Federal Register of Legislation - Australian Government

Primary content

PB 15 of 2011 Determinations/Health as made
This Determination amends the National Health (Price and Special Patient Contribution) Determination 2010 (No. PB 109 of 2010) by substituting Schedule 1 which is necessary to remove two brands of pharmaceutical items which previously attracted a brand premium and which are discontinued by the manufacturer, and also provides for an additional circumstance for when the Commonwealth will pay the special patient contribution for the listed drug naratriptan in the form tablet 2.5 mg (as hydrochloride).
Administered by: Health
Registered 23 Feb 2011
Tabling HistoryDate
Tabled HR24-Feb-2011
Tabled Senate28-Feb-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 15 of 2011

National Health (Price and Special Patient Contribution) Amendment Determination 2011 (No. 2)1

National Health Act 1953

I, FELICITY McNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Determination under section 85B of the National Health Act 1953.

Dated 18 February 2011

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

            (1)        This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2011 (No. 2).

            (2)        This Instrument may also be cited as PB 15 of 2011.

2          Commencement

                        This Instrument commences on 1 March 2011.

3          Amendment of PB 109 of 2010

                        Schedule 1 amends PB 109 of 2010.



Schedule 1     Amendments

 

[1]        Schedule 1, entry for Bleomycin

            omit:

 

 

Injection

Blenoxane

10

439.63

903.27

 

[2]        Schedule 1, entry for Pindolol

            omit:

 

Tablet 5 mg

Oral

Visken 5

100

4.18

6.42

 

[3]        Schedule 2, entry for Naratriptan

            insert after the second paragraph in the column headed “Circumstances”:

 

 

 

 

Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where drug interactions are expected to occur with other suitable PBS-listed drugs.

 

 

 

 

 

 

 

 

 

 

 

 

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.